A phase i clinical trial of dendritic cell immunotherapy in HCV-infected individuals

Journal of Hepatology

Volumn 53, Issue 4, 2010, Pages 599-607

  Gowans, Eric J ^a,i   Roberts, Stuart ^b   Jones, Kathryn ^a   Dinatale, Irene ^c   Latour, Philippe A ^a   Chua, Brendan ^c   Eriksson, Emily M Y ^c   Chin, Ruth ^d   Li, Shuo ^a   Wall, Dominic M ^e   Sparrow, Rosemary L ^f   Moloney, Jude ^e   Loudovaris, Maureen ^e   Ffrench, Rosemary ^a   Prince, H Miles ^e,g   Hart, Derek ^h   Zeng, Weng ^c   Torresi, Joseph ^d   Brown, Lorena E ^c   Jackson, David C ^c  

^a BURNET INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d AUSTIN HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h MATER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ CHILD HEALTH RESEARCH INSTITUTE   (Australia)

Author keywords

Cell therapy; ELIspot; Epitope; Interferon ; Therapeutic

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTYLLEUCYLMETHIONYLGLYCYLTYROSYLISOLEUCYLPROLYLLEUCYLVALINE; DENDRITIC CELL VACCINE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; ISOLEUCYLLEUCYLALANYLGLYCYLTYROSYLGLYCYLALANYLGLYCYLVALINE; LEUCYLLEUCYLPHENYLALANYLASPARAGINYLISOLEUCYLLEUCYLGLYCYLGLYCYLTRYPTOPHYLVALINE; LIPOPEPTIDE; LYSYLLEUCYLVALYLALANYLLEUCYLGLYCYLISOLEUCYLASPARAGINYLALANYLVALINE; PHENYLALANYLLEUCYLLEUCYLALANYLLEUCYLLEUCYLSERYLCYSTEINYLLEUCYLTHREONYLVALINE; TUMOR NECROSIS FACTOR ALPHA; TYROSYLLEUCYLLEUCYLPROLYLARGINYLARGINYLGLYCYLPROLYLARGINYLLEUCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; ANTIBODY RESPONSE; APHERESIS; ARTICLE; BODY TEMPERATURE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DRUG INDUCED HEADACHE; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE RASH; MALE; MONOCYTE; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; VACCINATION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; DENDRITIC CELLS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION;

EID: 77957756030     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.05.007     Document Type: Article

References (41)

1. D. Bowen, and C. Walker Adaptive immune responses in acute and chronic hepatitis C virus infection Nature 436 2005 946 952
2. R. Thimme, D. Oldach, K.M. Chang, C. Steiger, S.C. Ray, and F.V. Chisari Determinants of viral clearance and persistence during acute hepatitis C virus infections J Exp Med 194 2001 1395 1406
3. S.A. Villano, D. Vlahov, K.E. Nelson, S. Cohn, and D.L. Thomas Persistence of viremia and the importance of long-term follow up after acute hepatitis C infection Hepatology 29 1999 908 914
4. M. Gale, and E. Foy Evasion of intracellular host defence by hepatitis C virus Nature 436 2005 939 945
5. N. Kato, Y. Ootsuyama, H. Sekiya, S. Ohkoshi, T. Nakazawa, and M. Hijikata Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection J Virol 68 1994 4776 4784
6. A.L. Erickson, Y. Kimura, S. Igarashi, J. Eichelberger, M. Houghton, and J. Sidney The outcome of hepatitis C virus infection is predicted by escapte mutations in epitopes targeted by cytotoxic T lymphocytes Immunity 15 2001 883 895
7. S. Crotta, A. Stilla, A. Wack, A. D'Andrea, S. Nuti, and U. D'Oro Inhibition of natural killer cells through engagement of the CD81 by the major hepatitis C virus envelope protein J Exp Med 195 2002 35 41
8. C.T. Tseng, and G.R. Klimpel Binding of the hepatitis C virus E2 to CD81 inhibits natural killer cell function J Exp Med 195 2002 43 49
9. + T cell in chronic hepatitis C virus infection J Immunol 169 2002 3447 3458
10. E.J. Gowans, K.L. Jones, M. Bharadwaj, and D.C. Jackson Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus J Clin Virol 30 2004 283 290
11. H. Radziewicz, C.C. Ibegbu, M.L. Fernandez, K.A. Workowski, K. Obideen, and M. Wehbi Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression J Virol 81 2007 2545 2553
12. - regulatory T cells in chronic hepatitis C virus infection Immunol Cell Biol 85 2007 197 204
13. P.T. Donaldson The interrelationship between hepatitis C and HLA Eur J Clin Invest 29 1999 280 283
14. + lymphocytes share the same effector-memory phenotype but exhibit junctional differences in acute hepatitis B and C J Virol 76 2002 12423 12434
15. S. Urbani, B. Amadei, P. Fisicaro, D. Tola, A. Orlandini, and L. Sacchelli Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses Hepatology 44 2006 126 139
16. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
17. G.J. Randolph, S. Beaulieu, S. Lebecque, R.M. Steinman, and W.A. Muller Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking Science 282 1998 480 483
18. R.S. Longman, A.H. Talal, I.M. Jacobson, C.M. Rice, and M.L. Albert Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C J Infect Dis 192 2005 497 503
19. D. Piccioli, S. Tavarini, S. Nuti, P. Colombatto, M. Brunetto, and F. Bonino Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors J Hepatol 42 2005 61 67
20. R.S. Longman, A.H. Talal, I.M. Jacobson, M.L. Albert, and C.M. Rice Presence of functional dendritic cells in patients chronically infected with hepatitis C Blood 103 2004 1026 1029
21. B.Y. Chua, A. Healy, P. Cameron, N.L. Fowler, L.E. Brown, and W. Zeng Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus Immunol Cell Biol 81 2003 67 72
22. D.C. Jackson, G. Deliyannis, E. Eriksson, I. Dinatale, M. Rizkalla, and E.J. Gowans Dendritic cell immunotherapy of hepatitis C virus infection: toxicology of lipopeptide-loaded dendritic cells Int J Peptide Res Ther 11 2005 1 12
23. + T-cells without the addition of exogenous maturation factors J Viral Hepat 15 2008 761 772
24. W. Zeng, S. Ghosh, Y.F. Lau, L.E. Brown, and D.C. Jackson Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines J Immunol 169 2002 4905 4912
25. R. Trowbridge, T.P. Sloots, P. Buda, J. Faoagali, C. Hyland, and I. Young An ELISA for the detection of antibody to the core antigen of hepatitis C virus: use in diagnosis and analysis of indeterminate samples J Hepatol 24 1996 532 538
26. M. Larsson, E. Babcock, A. Grakoui, N. Shoukry, G. Lauer, and C. Rice Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus J Virol 78 2004 6151 6161 (Pubitemid 38715913)
27. + T cells and antiviral immunity Immunity 20 2004 47 58
28. H. Yu, H. Huang, J. Xiang, L.A. Babiuk, and S. van Drunen Littel-van den Hurk Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3 J Gen Virol 87 2006 1 10
29. N. Kuzushita, S.H. Gregory, N.A. Monti, R. Carlson, S. Gehring, and J.R. Wands Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens Gastroenterology 130 2006 453 464
30. J. Encke, J. Findeklee, J. Geib, E. Pfaff, and W. Stremmel Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection Clin Exp Immunol 142 2005 362 369
31. L.E. Brown, and D.C. Jackson Lipid-based self-adjuvanting vaccines Curr Drug Deliv 2 2005 383 393
32. H.M. Prince, D.M. Wall, D. Ritchie, D. Honemann, S. Harrison, and H. Quach In vivo tracking of dendritic cells in patients with multiple myeloma J Immunother 31 2008 166 179
33. B.A. Tjoa, S.J. Simmons, V.A. Bowes, H. Ragde, M. Rogers, and A. Elgamal Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides Prostate 36 1998 39 44
34. M. Smithers, K. O'Connell, S. MacFadyen, M. Chambers, K. Greenwood, and A. Boyce Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen Cancer Immunol Immunother 52 2003 41 52
35. E.R. Schiff, G.T. Everson, N. Tsai, N.H. Bzowej, R.G. Gish, and J.G. McHutchison HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: a randomized, double-blind, placebo controlled Phase 1B study Hepatology 44 2007 (Abs LB17)
36. F. Nevens, T. Roskams, H. Van Vlierberghe, Y. Horsmans, D. Sprengers, and A. Elewaut A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C Hepatology 38 2003 1289 1296
37. L. Alvarez-Lajonchere, N.H. Shoukry, Y. Amador-Canizares, B. Gra, F. Helle, and N. Bedard Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial J Viral Hepat 16 2009 156 167
38. C.S. Klade, H. Wedemeyer, T. Berg, H. Hinrichsen, G. Cholewinska, and S. Zeuzem Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41 Gastroenterology 134 2008 1385 1395
39. S. Yutani, A. Yamada, K. Yoshida, Y. Takao, M. Tamura, and N. Komatsu Phase 1 clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy Vaccine 25 2007 7429 7435
40. E. Lawitz, M. Rodriguez-Torres, A.J. Muir, T.L. Kieffer, L. McNair, and A. Khunvichai Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients J Hepatol 49 2008 163 169
41. A. Vulink, K. Radford, C. Melief, and D. Hart Dendritic cells in cancer immunotherapy Adv Cancer Res 99 2008 363 407